Seven and Eight Biopharmaceuticals to combine BDB001 with Roche’s Tecentriq
Seven and Eight Biopharmaceuticals Inc. and Roche agreed to trial a combination of the former’s BDB001 and latter’s Tecentriq (atezolizumab) in solid tumors.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com